Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. Show more

Location: 7 Times Square, New York, NY, 10036, United States | Website: https://dianthustx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

1.548B

52 Wk Range

$13.37 - $39.70

Previous Close

$38.88

Open

$38.97

Volume

22,417

Day Range

$38.26 - $38.97

Enterprise Value

1.29B

Cash

257.4M

Avg Qtr Burn

-25.06M

Insider Ownership

6.36%

Institutional Own.

Qtr Updated

06/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Claseprubart (DNTH103) Details Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Claseprubart (DNTH103) Details Multifocal Motor Neuropathy (MMN)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Claseprubart (DNTH103) Details Generalized Myasthenia Gravis (gMG)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MGTA-145 + plerixafor Details Multiple myeloma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.